Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication

Epilepsia

Volumn 41, Issue 5, 2000, Pages 581-587

  Hardus, P ^a   Verduin, W M ^a   Postma, G ^a   Stilma, J S ^a   Berendschot, T T J M ^a   Van Veelen, C W M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Concentric contraction; Epilepsy; Vigabatrin; Visual field loss

Indexed keywords

VIGABATRIN;

ADULT; ARTICLE; DISEASE SEVERITY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEIZURE; TEMPORAL LOBE EPILEPSY; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

EID: 0034097849     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb00212.x     Document Type: Article

References (19)

1. International Council of Ophthalmology. Perimetric standards and perimetric glossary. The Hague: Dr. W. Junk Publishers, 1979.
2. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;314:180-1.
3. Blackwell N, Hayllar J, Kelly G. Severe persistent visual field constrictions associated with vigabatrin. Br Med J 1997;314:1694.
4. Wong IC, Mawer GE, Sander JW. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;314:1 693-4.
5. Wilson EA, Brodie MJ. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;314:1693.
6. Mackenzie R, Klistorner A. Asymptomatic as well as symptomatic defects occur with vigabatrin. Br Med J 1997;316:233.
7. Kraemer G, Scollo-Lavizzari G, Jallon P, et al. Vigabatrin-associated bilateral concentric visual field defects in four patients [Abstract]. Epilepsia 1997;38(suppl 8):179.
8. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction. Neurology 1998;50:614-8.
9. Harding G, Wild J, Robertson K, et al. Electrooculography, ERGs, multifocal ERGs and VEPs in epileptic patients showing visual field disorders. Electroencephalogr Clin Neurophysiol 1997;103: 96.
10. Martinez C, Noack H. The risk of visual field defects and the use of vigabatrin. Denham: Hoechst Marion Roussel, 1997 (Internal Report).
11. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999;106:1792-8.
12. Petroff OA, Rothman DL, Behar KL, Collins TL, Mattson RH. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology 1996;47:1567-71.
13. Hinkle R. Vigabatrin Postmarketing Surveillance-Estimate of Patient Exposure 1989-1996. Denham: Hoechst Marion Roussel, 1998 (Internal Report).
14. Veelen van CWM, Debets RMC, Huffelen van AC, Emde Boas van W. Dutch Collaborative Epilepsy Surgery Program: Presurgical Evaluation. In: Engel J Jr, ed. Surgical treatment of the epilepsies. New York: Raven Press, 1993:711-2.
15. Greve EL. Single and multiple stimulus static perimetry in glaucoma: the two phases of perimetry. PhD Thesis. The Hague: Dr. W. Junk Publishers, 1973.
16. American Medical Association. Guides to the evaluation of permanent impairment. 4th ed. Chicago: American Medical Association, 1993.
17. Harding GFA. Severe persistent visual field loss with vigabatrin. Br Med J 1997;314:1694.
18. Ruether K, Pung T, Kellener U, Schmitz B, Hartmann C, Seliger M. Electrophysiological evaluation of a patient with visual field contraction associated with vigabatrin. Arch Ophthalmol 1998; 116:817-9.
19. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol 1989;27(suppl 1):43-53.